Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Weiyi Peng, Jie Qing Chen, Chengwen Liu, et al.
Cancer Discovery (2015) Vol. 6, Iss. 2, pp. 202-216
Open Access | Times Cited: 1345

Showing 1-25 of 1345 citing articles:

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma, Siwen Hu‐Lieskovan, Jennifer A. Wargo, et al.
Cell (2017) Vol. 168, Iss. 4, pp. 707-723
Open Access | Times Cited: 4390
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo, Jesse M. Zaretsky, Lu Sun, et al.
Cell (2016) Vol. 165, Iss. 1, pp. 35-44
Open Access | Times Cited: 2959
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
Vyara Matson, Jessica Fessler, Riyue Bao, et al.
Science (2018) Vol. 359, Iss. 6371, pp. 104-108
Open Access | Times Cited: 2469
The PI3K Pathway in Human Disease
David A. Fruman, Honyin Chiu, Benjamin D. Hopkins, et al.
Cell (2017) Vol. 170, Iss. 4, pp. 605-635
Open Access | Times Cited: 2171
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel, Diego Chowell, Timothy A. Chan
Nature reviews. Cancer (2019) Vol. 19, Iss. 3, pp. 133-150
Open Access | Times Cited: 1956
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, et al.
Cancer Discovery (2018) Vol. 8, Iss. 7, pp. 822-835
Open Access | Times Cited: 1294
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Daniela Bruni, Helen K. Angell, Jérôme Galon
Nature reviews. Cancer (2020) Vol. 20, Iss. 11, pp. 662-680
Closed Access | Times Cited: 1205
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger, Daisy Dai, Brendan Horton, et al.
Cancer Cell (2017) Vol. 31, Iss. 5, pp. 711-723.e4
Open Access | Times Cited: 1188
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Yosuke Togashi, Kohei Shitara, Hiroyoshi Nishikawa
Nature Reviews Clinical Oncology (2019) Vol. 16, Iss. 6, pp. 356-371
Closed Access | Times Cited: 1185
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi, Antoni Ribas
Nature reviews. Immunology (2019) Vol. 20, Iss. 1, pp. 25-39
Open Access | Times Cited: 1181
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby‐Arnon, Parin Shah, Michael S. Cuoco, et al.
Cell (2018) Vol. 175, Iss. 4, pp. 984-997.e24
Open Access | Times Cited: 1173
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins, David A. Barbie, Keith T. Flaherty
British Journal of Cancer (2018) Vol. 118, Iss. 1, pp. 9-16
Open Access | Times Cited: 1143
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke, Keith T. Flaherty, Antoni Ribas, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 8, pp. 463-482
Closed Access | Times Cited: 1089
Therapeutic cancer vaccines
Mansi Saxena, Sjoerd H. van der Burg, Cornelis J.M. Melief, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 6, pp. 360-378
Closed Access | Times Cited: 1082
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Golnaz Morad, Beth A. Helmink, Padmanee Sharma, et al.
Cell (2021) Vol. 184, Iss. 21, pp. 5309-5337
Open Access | Times Cited: 1070
Therapeutic cancer vaccines
Cornelis J.M. Melief, Thorbald van Hall, Ramon Arens, et al.
Journal of Clinical Investigation (2015) Vol. 125, Iss. 9, pp. 3401-3412
Open Access | Times Cited: 1038
T Cell Dysfunction in Cancer
Daniela S. Thommen, Ton N. Schumacher
Cancer Cell (2018) Vol. 33, Iss. 4, pp. 547-562
Open Access | Times Cited: 1007
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro, Pablo Sarobe, Sandra Hervás‐Stubbs, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 8, pp. 525-543
Open Access | Times Cited: 938
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt, Marie Vétizou, Romain Daillère, et al.
Immunity (2016) Vol. 44, Iss. 6, pp. 1255-1269
Open Access | Times Cited: 930
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura, Tala Shekarian, Vincent Alcazer, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 930
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip J. Gotwals, Scott B. Cameron, Daniela Cipolletta, et al.
Nature reviews. Cancer (2017) Vol. 17, Iss. 5, pp. 286-301
Closed Access | Times Cited: 867
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Valsamo Anagnostou, Kellie N. Smith, Patrick M. Forde, et al.
Cancer Discovery (2016) Vol. 7, Iss. 3, pp. 264-276
Open Access | Times Cited: 794
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Science Translational Medicine (2017) Vol. 9, Iss. 379
Open Access | Times Cited: 778
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu, Bastian Schilling, Derek Liu, et al.
Nature Medicine (2019) Vol. 25, Iss. 12, pp. 1916-1927
Open Access | Times Cited: 773
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis, John V. Heymach
Nature reviews. Cancer (2019) Vol. 19, Iss. 9, pp. 495-509
Open Access | Times Cited: 772
Page 1 - Next Page

Scroll to top